IL152428A0 - Formulations and method of using nitric oxide mimetics against a malignant cell phenotype - Google Patents

Formulations and method of using nitric oxide mimetics against a malignant cell phenotype

Info

Publication number
IL152428A0
IL152428A0 IL15242801A IL15242801A IL152428A0 IL 152428 A0 IL152428 A0 IL 152428A0 IL 15242801 A IL15242801 A IL 15242801A IL 15242801 A IL15242801 A IL 15242801A IL 152428 A0 IL152428 A0 IL 152428A0
Authority
IL
Israel
Prior art keywords
formulations
nitric oxide
cell phenotype
malignant cell
oxide mimetics
Prior art date
Application number
IL15242801A
Other languages
English (en)
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Publication of IL152428A0 publication Critical patent/IL152428A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15242801A 2000-04-26 2001-04-26 Formulations and method of using nitric oxide mimetics against a malignant cell phenotype IL152428A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19975700P 2000-04-26 2000-04-26
US27746901P 2001-03-21 2001-03-21
PCT/CA2001/000566 WO2001080890A2 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Publications (1)

Publication Number Publication Date
IL152428A0 true IL152428A0 (en) 2003-05-29

Family

ID=26895114

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15242801A IL152428A0 (en) 2000-04-26 2001-04-26 Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
IL152428A IL152428A (en) 2000-04-26 2002-10-22 Nitric oxide mimetic compositions for use against a malignant cell phenotype

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152428A IL152428A (en) 2000-04-26 2002-10-22 Nitric oxide mimetic compositions for use against a malignant cell phenotype

Country Status (12)

Country Link
US (1) US6946484B2 (de)
EP (1) EP1278547B1 (de)
JP (1) JP2003531179A (de)
AT (1) ATE281177T1 (de)
AU (2) AU2001250221B2 (de)
CA (1) CA2407466C (de)
DE (1) DE60106905T2 (de)
ES (1) ES2232613T3 (de)
HK (1) HK1052468B (de)
IL (2) IL152428A0 (de)
MX (1) MXPA02010551A (de)
WO (1) WO2001080890A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
JP2005527510A (ja) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
EP1648475B1 (de) 2003-07-09 2007-09-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
SE0401871D0 (sv) * 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
JP5184087B2 (ja) * 2004-09-22 2013-04-17 トリパス イメージング， インコーポレイテッド ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
WO2006125123A2 (en) 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP2669269B1 (de) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
US8766512B2 (en) * 2009-03-31 2014-07-01 Sand 9, Inc. Integration of piezoelectric materials with substrates
US20100221247A1 (en) * 2008-09-29 2010-09-02 Robert Bender Agents and methods for treatment of cancer
CA2771308C (en) 2009-08-21 2020-01-21 Novan, Inc. Topical gels comprising nitric oxide releasing polysiloxane macromolecules
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
EP2681286B1 (de) 2011-02-28 2018-08-15 Novan, Inc. Stickoxid-freisetzende s-nitrosothiol-modifizierte kieselsäureteilchen und verfahren zu ihrer herstellung
KR101969526B1 (ko) * 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 악성 종양 전이 억제용 의약
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
USD974802S1 (en) * 2013-06-16 2023-01-10 Bengt Johansson Flooring guard for pets
USD949597S1 (en) 2014-06-15 2022-04-26 Bengt Johansson Flooring guard for pets
USD975470S1 (en) * 2014-06-15 2023-01-17 Bengt Johansson Flooring guard for pets
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3936145A1 (de) * 2014-07-31 2022-01-12 The University Of Western Australia Verfahren zur identifizierung von immuntherapie-arzneimittel-kombinationen unter verwendung eines netzwerkansatzes
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
MX2018002121A (es) 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
EP3449004B1 (de) 2016-04-29 2021-02-24 Poseida Therapeutics, Inc. Mizellen auf poly(histidin)-basis zur komplexierung und abgabe von proteinen und nukleinsäuren
EP3464573A4 (de) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
KR20200144116A (ko) * 2018-04-16 2020-12-28 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
EP0722320B1 (de) * 1993-10-08 2000-07-19 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
LV11542B (en) 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US5849790A (en) 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
DE19732323C2 (de) * 1996-08-06 1999-08-19 Dunzendorfer Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6610660B1 (en) 1996-09-27 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates
WO1999003462A1 (en) 1997-07-14 1999-01-28 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
EP1060174B1 (de) 1997-12-23 2004-09-22 Amersham Health AS Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
CA2330628A1 (en) 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
WO2000051597A1 (en) 1999-03-05 2000-09-08 Merck Frosst Canada & Co. Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
AU2001234602A1 (en) 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
AU2001247579B2 (en) 2000-03-20 2005-01-06 Novovascular, Inc. Matrices containing nitric oxide donors and reducing agents and their use
US20010038832A1 (en) 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
DE60106905D1 (de) 2004-12-09
US20020040059A1 (en) 2002-04-04
WO2001080890A3 (en) 2002-08-08
HK1052468B (zh) 2005-06-03
HK1052468A1 (en) 2003-09-19
EP1278547A2 (de) 2003-01-29
ATE281177T1 (de) 2004-11-15
AU2001250221B2 (en) 2006-07-06
MXPA02010551A (es) 2003-09-25
CA2407466C (en) 2010-11-02
DE60106905T2 (de) 2005-12-01
CA2407466A1 (en) 2001-11-01
IL152428A (en) 2011-06-30
EP1278547B1 (de) 2004-11-03
JP2003531179A (ja) 2003-10-21
ES2232613T3 (es) 2005-06-01
WO2001080890A2 (en) 2001-11-01
AU5022101A (en) 2001-11-07
US6946484B2 (en) 2005-09-20

Similar Documents

Publication Publication Date Title
IL152428A0 (en) Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
AU5984701A (en) Method of treating immune pathologies with low dose estrogen
GB2368283A (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AP2002002703A0 (en) Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
HK1054918A1 (en) Compounds and compositions for delivering active agents
EP1414451A4 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
HK1125291A1 (en) Method of using guava extract and composition including guava extract
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
MXPA02011247A (es) Quimioterapia de combinacion.
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
MXPA02011431A (es) Composiciones y metodos para usar contra la inflamacion inducida por acne y enzimas que degradan la matriz dermica.
WO2002022145A3 (en) Components of canola for the treatment of cancer
WO2000047231A3 (en) Novel antisense inhibition of rad51
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
ZA986720B (en) Photoresponsive sunscreen compositions
GEP20074075B (en) Indazolamides with analgesic activity
AP2000001926A0 (en) Voacamine as anti-malarial agent and anti-malarial agent containing voacamine.
DE60320283D1 (de) Zusammensetzungen mit Amphotericin B enthaltend weniger als 4% Verunreinigungen
AU2204400A (en) Monte carlo simulation of neutron transport for use in radiotherapy
EP1289570A4 (de) Liposomale einkapselung von cheliertem aktinium-225, und deren verwendung
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
WO2006036956A3 (en) Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents